FDA Approves New CooperVision Biofinity Toric Multifocal Contact Lenses


SAN RAMON, Calif.—CooperVision Inc. announced this week that the Food and Drug Administration (FDA) has granted approval for its new Biofinity toric multifocal contact lenses. The new lens combines the proven optical designs of CooperVision’s Biofinity toric—the most prescribed toric lens on the market—and Biofinity multifocal to provide patients with both the astigmatism and presbyopia vision correction they deserve, the company noted. CooperVision said it plans to make the lenses available to U.S. eyecare professionals later this year, with launches following in other markets.

“Biofinity toric multifocal extends the reliable performance of our Biofinity toric lenses to presbyopic patients,” Michele Andrews, OD, senior director, professional and academic affairs, North America, CooperVision, said in the announcement. “U.S. eyecare professionals will soon have an easy-to-fit, familiar lens design they can count on to keep current toric wearers satisfied in contact lenses for longer, and provide new astigmatic wearers an alternative to reading glasses. It’s a win-win for practitioners and their patients.”

Lens parameters and other details regarding Biofinity toric multifocal will be made public in the coming months, the company said. For more information, visit https://coopervision.com/practitioner/only-biofinity-toric-multifocal.

CooperVision, a unit of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses.